Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy

Climacteric

Volumn 19, Issue 1, 2016, Pages 60-65

  Bruyniks, N ^a   Nappi, R E ^b   Castelo Branco, C ^c   De Villiers, T J ^d   Simon, J ^e  

^a BrInPhar Ltd   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

ospemifene; randomized clinical trials; Vulvar and vaginal atrophy

Indexed keywords

OSPEMIFENE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; VAGINA ATROPHY; VAGINAL DRYNESS; VULVA ATROPHY; VULVA DISEASE; VULVA PRURITUS; ADULT; AGED; ANALOGS AND DERIVATIVES; ATROPHY; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; VAGINA; VAGINAL DISEASES; VERY ELDERLY; VULVA;

ADULT; AGED; AGED, 80 AND OVER; ATROPHY; DOUBLE-BLIND METHOD; DYSPAREUNIA; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PRURITUS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA;

EID: 84954026906     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2015.1113517     Document Type: Article

References (16)

1. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009; 16: 735-41
2. Nappi RE, Mattsson L-Å, Lachowsky M, Maamari R, Giraldi A. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas 2013; 75: 373-9
3. Parish SJ, Nappi RE, Krychman ML., et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437-47
4. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94
5. Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, de Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015; 18: 233-40
6. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17: 3-9
7. Dennerstein L, Dudley E, Hopper J, Guthrie J, Burger H. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96: 351-8
8. Weber MA, Limpens J, Roovers JPWR. Assessment of vaginal atrophy: a review. Int Urogynecology J 2015; 26: 15-28
9. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Womens VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10: 1790-9
10. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation. Draft guidance, Food and Drug Administration. January 2003. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071643.pdf [Last accessed July 2015]
11. Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008; 15: 885-9
12. Chen L, Ng M-J, van der Vlugt TH, Price PH, Orencia A. Statistical considerations for the efficacy assessment of clinical studies of vulvar and vaginal atrophy. Drug Inf J 2010; 44: 581-8
13. Bachmann GA, Komi JO,; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: 480-6
14. Portman DJ, Bachmann GA, Simon JA,; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-30
15. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014; 78: 91-8
16. Goldstein I, Dicks B, Kim NN, Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med 2013; 1: 44-53